WorldHeart Reports 2009 Financial Results

Tuesday, March 2, 2010 Press Release
Email Print This Page Comment bookmark
Font : A-A+

SALT LAKE CITY, March 1 ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation, a developer of mechanical circulatory systems, today reported the net loss for the year ended December 31, 2009 of $16.7 million, or a $1.26 loss per basic and diluted share, compared to a $25.3 million net loss, or a $4.37 loss per basic and diluted share in 2008. The decrease was primarily the result of one-time, non-cash clinical and marketing expenses of $6.5 million and one-time debt inducement expense of $3.9 million that we recognized in 2008 related to warrants issued to a strategic partner and the subsequent conversion of debt to common stock. The decrease in clinical and marketing expenses and the debt inducement expense in 2009 was offset by increases in research and development expenses as well as selling, general and administrative expenses. These increased costs are associated with the preparation for the Levacor(TM) VAD Bridge-to-Transplant (BTT) clinical study which received unconditional approval from the U.S. Food and Drug Administration in January 2010.

Revenues were $5,000 for the year ended December 31, 2009, as compared to $1.7 million for the year ended December 31, 2008. The decrease in revenue from 2008 to 2009 is the result of our November 2006 decision to suspend our commercial efforts with respect to the Novacor LVAS and focus our efforts and resources in the development of the Levacor VAD. In 2007 and 2008, we made the Novacor LVAS available to medical centers only until our inventory was depleted, which occurred in mid-2008. Additionally, we did not have any SPUS (Segmented Poly Urethane Solution) revenue in 2009 as compared to $785,000 in 2008. The decrease is a result of this revenue being associated with one customer who placed no orders in 2009.

At December 31, 2009 our balance sheet reflected $6.1 million in cash, cash equivalents and marketable investment securities, which is exclusive of the $7.1 million in net proceeds from the January 2010 private placement. This compares to $20.7 million in cash and cash equivalents at December 31, 2008.

"With our unconditional approval for the BTT clinical study in January coupled with the financing we recently completed, we are well positioned to move our Levacor VAD program forward. We are excited to offer the world's only fully magnetically levitated, bearingless, implantable centrifugal pump to heart failure patients in the U.S.," added Mr. J. Alex Martin, President and Chief Executive Officer.

About WorldHeart

WorldHeart is a developer of mechanical circulatory support systems headquartered in Salt Lake City, Utah. World Heart's registered office is in Delaware, USA.

Forward-Looking Statements

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the proposed use of proceeds, of the private placement, increase in shareholder value, access to investment capital, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; risks involved in the Levacor VAD Bridge-to-Transplant (BTT) clinical study; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.

WORLD HEART CORPORATION Condensed Consolidated Balance Sheets (United States Dollars) (Unaudited) December 31, 2009 December 31, 2008 ----------------- ----------------- ASSETS Current assets Cash and cash equivalents $5,562,670 $20,703,724 Marketable investment securities 499,417 - Trade and other receivables, net 18,907 322,548 Inventory, net 341,614 - Prepaid expenses and other current assets 271,966 458,294 ------- ------- 6,694,574 21,484,566 Long-term assets Property and equipment, net 879,833 651,572 Intangible assets, net - 107,916 Other long-term assets 36,360 156,360 ------ ------- 916,193 915,848 ------- ------- Total assets $7,610,767 $22,400,414 ========== =========== LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities $1,522,199 $1,388,675 Accrued compensation 645,306 897,086 Note payable - short term 102,877 - Deferred rent 18,967 3,671 ------ ----- 2,289,349 2,289,432 --------- --------- Long-term liabilities Note payable - long term 580,123 - Other long term liabilities 82,309 - ------ --- Total liabilities 2,951,781 2,289,432 --------- --------- Commitments and Contingencies Shareholders' equity Common stock, no par value, 13,312,265 shares issued and 325,279,751 325,087,252 Additional paid-in-capital 18,389,635 17,323,629 Cumulative other comprehensive loss (6,285,577) (6,285,577) Accumulated deficit (332,724,823) (316,014,322) ------------ ------------ Total shareholders' equity 4,658,986 20,110,982 --------- ---------- Total liabilities and shareholders' equity $7,610,767 $22,400,414 ========== =========== WORLD HEART CORPORATION Condensed Consolidated Statements of Operations (United States Dollars) Year Ended December 31, ----------------------- 2009 2008 ---- ---- Revenue $4,765 $1,732,143 Cost of goods sold (212,975) (992,197) -------- -------- Gross profit (loss) (208,210) 739,946 -------- ------- Operating expenses Research and development 10,111,152 9,047,531 Selling, general and administrative 5,682,295 4,752,372 Clinical and marketing support - 6,478,619 Restructuring costs 577,666 131,431 Amortization of intangibles 107,916 191,424 ------- ------- Total operating expenses 16,479,029 20,601,377 ---------- ---------- Operating loss (16,687,239) (19,861,431) Other income (expenses) (23,262) (5,455,353) ------- ---------- Net loss $(16,710,501) $(25,316,784) ============ ============ Weighted average number of common shares outstanding: basic and diluted 13,273,462 5,798,940 ========== ========= Basic and diluted loss per common share $(1.26) $(4.37) ====== ======

SOURCE World Heart Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store